MedTrace Logo

AI Assisted the Diagnosis of Pancreatic Solid Lesions

NCT05706415 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-01-31

No results posted yet for this study

Summary

Solid lesions of the pancreas mainly include tumor and non tumor lesions. More than 90% of pancreatic tumor lesions are pancreatic cancer, which is characterized by high mortality and poor prognosis and requires surgical treatment; Non-tumor lesions of the pancreas are mainly inflammatory lesions, which usually do not require surgical treatment, but can be treated with drugs. The common ones are chronic pancreatitis and autoimmune pancreatitis, with a good prognosis. Clinically, the differential diagnosis between them is very difficult. Multi-disciplinary diagnosis and treatment of MDT makes our understanding of pancreatic diseases increasingly rich and in-depth. From disease diagnosis to preoperative evaluation and curative effect evaluation, non-invasive imaging involves almost every link under MDT mode. In view of this, improving the differential diagnosis of pancreatic solid space-occupying lesions on imaging will be more conducive to the diagnosis and treatment under MDT mode, so new technologies such as artificial intelligence should be considered. Our goal is to develop a clinically applicable artificial intelligence system, which uses multiple modes to simulate the routine clinical workflow and assist in the diagnosis of benign and malignant pancreatic solid space-occupying lesions.

Conditions

  • AI Assist in the Diagnosis of Pancreatic Solid Lesions

Interventions

DIAGNOSTIC_TEST

Clinicians will review the suggestions of a hypothetical AI

There is no intervention. Clinicians will review the suggestions of a hypothetical AI

Sponsors & Collaborators

  • The Third People's Hospital of Chengdu

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Changhai Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-21
Primary Completion
2023-02-21
Completion
2023-02-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05706415 on ClinicalTrials.gov